Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial Axel Grothey Clinical Trials Report 01 April 2009 Pages: 65 - 66
The role of inflammation in the pathogenesis of colorectal cancer Beth B. McConnellVincent W. Yang OriginalPaper 01 April 2009 Pages: 69 - 74
The serrated pathway of colorectal carcinogenesis Vicki L.J. WhitehallBarbara A. Leggett OriginalPaper 01 April 2009 Pages: 75 - 83
The epigenome of colorectal cancer Minoru ToyotaHiromu SuzukiYasuhisa Shinomura OriginalPaper 01 April 2009 Pages: 84 - 89
Internal radioembolization for colorectal carcinoma liver metastases Saad M. IbrahimAhsun RiazRiad Salem OriginalPaper 01 April 2009 Pages: 93 - 98
Recent progress in imaging of colorectal cancer liver metastases Surabhi BajpaiDushyant V. Sahani OriginalPaper 01 April 2009 Pages: 99 - 107
Chemotherapy-associated liver injury: Does it really matter? Thomas A. AloiaBridget N. Fahy OriginalPaper 01 April 2009 Pages: 108 - 113
Do we need biologic agents in preoperative systemic therapy of liver metastases? Steven R. Alberts OriginalPaper 01 April 2009 Pages: 114 - 119
Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer Patricia L. MyskowskiAllan C. Halpern OriginalPaper 01 April 2009 Pages: 120 - 125